Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in a related lung disease leading the drugmaker to expand the indications ...

The scarring causes stiffness in the lungs which makes it difficult to breathe and get oxygen to the bloodstream.[i] Boehringer Ingelheim, in collaboration with Emirates Thoracic Society (ETS) and ...